Cramer Hails Johnson & Johnson as Market Anchor Amid AI Sector Slump
Investors are rotating into defensive healthcare stocks like Johnson & Johnson as tech shares decline, a trend highlighted by CNBC's Jim Cramer.
By Samuel Ellis ·

Johnson & Johnson is emerging as a standout performer in the current market environment, serving as a clear example of stocks that are thriving while investors move away from the volatile artificial intelligence trade. On Monday, CNBC's Jim Cramer described the pharmaceutical and medical technology giant as a metaphor for what is working in the broader stock market. This assessment came as shares of the company reached a new all-time high before reversing lower during a difficult trading session.
The shift in investor sentiment reflects a broader rotation into defensive sectors, including healthcare and consumer staples, as companies tied to the AI boom face significant headwinds. Cramer noted that this evolving dynamic has been a key focus for his investment club in recent weeks. The group has been reducing its exposure to data centers and diversifying its portfolio into these more stable defensive areas, a strategy that was a central theme at their annual meeting earlier this month.
Market data supports this trend, with healthcare and consumer staples acting as the top performers over the past month. These sectors posted gains of 7% and 6%, respectively, which significantly outpaced the S&P 500, which saw a decline of nearly 3%. In contrast, the technology sector suffered a drop of more than 9% over the same period. This weakness is attributed to concerns about how a potential Democratic wave in the midterm elections might impact the ongoing buildout of data centers, alongside uncertainty stemming from a recent leadership scandal at Nvidia.
Cramer emphasized the stark difference between these two corporate giants, stating that Johnson & Johnson is the exact opposite of Nvidia. He characterized the pharma company as a clean entity that is widely favored by investors. This positive outlook aligns with the club's actions, as they initiated a position in Johnson & Johnson in early April. Since that time, the stock has appreciated by 20% and recorded a record-high close on Friday.
The recent upward momentum was further bolstered by a strategic acquisition announced on Monday. Johnson & Johnson plans to purchase Ollin Biosciences, a clinical-stage biopharmaceutical company, for $2.2 billion upfront. The deal includes an additional payment of up to $1.13 billion contingent on meeting certain milestones. This acquisition is designed to expand the company's portfolio of treatments for serious eye diseases.
Cramer has maintained a bullish stance on the company for some time, citing its robust pipeline of drugs. Key products include leading treatments for blood cancer and Icotyde, a unique oral solution for plaque psoriasis. The company has also successfully navigated a major legal challenge related to its talc products, a headwind that had weighed on its performance for several years.
Beyond its product pipeline, Cramer highlighted the company's strong fundamentals and the effective execution of its management team. Last month, Johnson & Johnson reported third-quarter revenue and earnings that exceeded expectations. Despite these positive results, the stock initially dropped nearly 6% following the release, driven by disappointing performance in its MedTech segment and a historical tendency for the shares to decline on earnings days.
Cramer argued that investors often overlook the underlying strength of the company immediately after quarterly releases, only to recognize its value later. He noted that the pharmaceutical side of the business offers much to like, providing comfort against the temporary weakness in the medical technology division. The company is also taking steps to enhance future MedTech growth through a planned spin-off of its orthopedics business by 2027. Johnson & Johnson is scheduled to report its fourth-quarter results next month.
Cramer's charitable trust currently holds a long position in Johnson & Johnson. As a subscriber to the CNBC Investing Club, members receive trade alerts before Cramer executes trades in his portfolio. He waits 45 minutes after sending an alert before buying or selling, and if he has discussed the stock on television, he waits 72 hours after the alert before executing the trade.
More News · National news · Report a business · Got a Story?






